Stock LBPH LONGBOARD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
18.01 USD +5.94% Intraday chart for Longboard Pharmaceuticals, Inc. -11.93% +198.67%
Mar. 26 Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
Mar. 18 Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI

Evolution of the average Target Price on Longboard Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

37686eba2d87.q6hGrVhy4tZY4G0lfYbKJKimyt-dODln2B4fmNoza-8.4d4PlWo4kbIxjQJ1J-Owe-Lso-rCblYEr0tl0_djApnjmhz0LQaV-xSKBg~8b7c8384e3bad35f368f4c46d6d4f5fc

Analyst Recommendations on Longboard Pharmaceuticals, Inc.

Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $55 From $35, Maintains Overweight Rating MT
Guggenheim Raises Longboard Pharmaceuticals' Price Target to $32 From $16, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $22 From $11, Says PACIFIC Data Readout Provides Best-Case Scenario for Bexicaserin (LP352); Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Longboard Pharmaceuticals to $16 From $11, Keeps Overweight Rating MT
B. Riley Initiates Longboard Pharmaceuticals at Buy With $13 Price Target, Believes Shares Are Undervalued MT
Citigroup Cuts Price Target on Longboard Pharmaceuticals to $17 From $24, Maintains Buy Rating MT
Guggenheim Trims Price Target on Longboard Pharmaceuticals to $16 From $18, Maintains Buy Rating MT
Wedbush Trims Longboard Pharmaceuticals' Price Target to $11 From $12, Keeps Outperform Rating MT
Wedbush Cuts Price Target on Longboard Pharmaceuticals to $12 From $14 'on Lower Net Cash;' Outperform Rating Kept MT
HC Wainwright Initiates Longboard Pharmaceuticals at Buy with $25 Price Target MT
Wedbush Starts Longboard Pharmaceuticals at Outperform With $14 Price Target MT
LONGBOARD PHARMACEUTICALS : Evercore ISI Starts Longboard Pharmaceuticals at Outperform with $35 Price Target MT
LONGBOARD PHARMACEUTICALS : Citigroup Initiates Longboard Pharmaceuticals at Buy Rating With $37 Price Target MT
LONGBOARD PHARMACEUTICALS : Cantor Fitzgerald Initiates Longboard Pharmaceuticals at Overweight Rating With $32 Price Target MT
LONGBOARD PHARMACEUTICALS : Guggenheim Initiates Longboard Pharmaceuticals at Buy Rating With $27 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
18.01 USD
Average target price
42.57 USD
Spread / Average Target
+136.38%
High Price Target
60 USD
Spread / Highest target
+233.15%
Low Price Target
30 USD
Spread / Lowest Target
+66.57%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Longboard Pharmaceuticals, Inc.

Cantor Fitzgerald
B. Riley
Wedbush
HC Wainwright
Guggenheim
Citigroup
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LBPH Stock
  4. Consensus Longboard Pharmaceuticals, Inc.